IREL AND’S No.1 Sl eep A Id BRAND CAN H E LP YOU GET A GOOD NIGHT’S SLEEP

*Based on IQVIA sales data MAT 07/2022.

Clinically Proven

Nytol One-A-Night 50 mg Tablets contains diphenhydramine hydrochloride. A symptomatic aid to the relief of temporary sleep disturbance in adults. Adults: One tablet to be taken 20 minutes before going to bed, or as directed by a physician. Do not exceed the maximum dose of one tablet in 24 hours. Elderly patients or patients with liver or kidney problems should consult their doctor before taking this medicine. Children under 18 years: Not recommended. The product should not be taken for more than 7 days without consulting a doctor. Contraindications: Hypersensitivity to the active substance or to any of the excipients, stenosing peptic ulcer, pyloroduodenal obstruction, phaeochromocytoma, known acquired or congenital QT interval prolongation, known risk factors for QT interval prolongation. Special warnings and precautions: Pregnancy/lactation, renal and hepatic impairment, myasthenia gravis, epilepsy or seizure disorders, narrow-angle glaucoma, prostatic hypertrophy, urinary retention, asthma, bronchitis, COPD. Patients should be advised to promptly report any cardiac symptoms. Tolerance and / or dependence may develop with continuous use. Do not take for more than 7 consecutive nights without consulting a doctor. Should not be used in patients currently receiving MAO inhibitors (MAOI) or patients who have received treatment with MAOIs within the last two weeks Use in the elderly should be avoided. Avoid concomitant use of alcohol or other antihistamine-containing preparations. Do not drive or operate machines. Cases of abuse and dependence were reported in adolescents or young adults for recreational use and/or in patients with psychiatric dis-orders and/or history of abuse disorders. Contains lactose. May suppress the cutaneous histamine response to allergen extracts and should be stopped several days before skin testing. Interactions: Alcohol, CNS depressants, MAO inhibitors, anticholinergic drugs (e.g. atropine, tricyclic antidepressants), metoprolol and venlafaxine, CYP2D6 inhibitors, Class Ia and Class III anti-arrhythmics. Side effects: Dry mouth, fatigue, sedation, drowsiness, disturbance in attention, unsteadiness, dizziness, thrombocytopenia, hypersensitivity reactions, confusion, paradoxical excitation, convulsions, headache, paraesthesia, dyskinesias, blurred vision, tachycardia, palpitations, thickening of bronchial secretions, gastrointestinal disturbance, muscle twitching, urinary difficulty, urinary retention. Legal classification: P. PA1186/016/001. MAH: Chefaro Ireland DAC. The Sharp Building. Hogan Place. Dublin 2. Ireland. Date of preparation: 07/2022. RRP (ex. VAT): 20s €9.00. SPC: https://www.medicines.ie/medicines/nytol-one-a-night-50-mg-tablets-34889/smpc IRE NYT

ALZECURE ACHIEVES LAST PATIENT LAST VISIT (LPLV) IN ITS PHASE II CLINICAL TRIAL OF THE NON-OPIOID ACD440 IN NEUROPATHIC PAIN

AlzeCure Pharma AB (publ) (FN STO: ALZCUR) a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, has announced that the Last Patient Last Visit (LPLV) has now been completed in the ongoing phase II clinical trial with ACD440, the lead non-opioid drug candidate in the Painless platform, which is being developed against peripheral neuropathic pain.

”We look forward to seeing the results of this important phase II trial in peripheral neuropathic pain, an area of very high medical need where up to 80% of patients are not responding satisfactorily with their current treatments and where many are still prescribed opioids”, said Märta Segerdahl, project leader and CMO at AlzeCure Pharma. This double-blind, placebocontrolled, randomized cross-over study, which is carried out in collaboration with LINK Medical Research in Sweden, is aimed at evaluating the efficacy, safety and pharmacokinetics of AlzeCure’s lead drug candidate in pain, ACD440. The main results from the study are expected by the summer of 2023 at the latest.

AlzeCure’s drug candidate

ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. The discovery of TRPV1 that underlies the project was awarded the Nobel Prize in Physiology or Medicine in 2021. There is thus a strong scientific basis for this biological mechanism, including its relationship to pain signaling. ACD440, which is also the company’s leading drug candidate within the Painless platform, completed a positive phase Ib study in 2021. It showed both very good tolerability and safety, but also a potent, long-lasting painrelieving effect of the substance that is applied as a gel to the skin. The medical need in neuropathic pain is very great, not least to find alternatives to opioids. The neuropathic pain market is the single largest market segment in pain management with annual sales exceeding $11 billion. Up to 80% of patients do not get a satisfactory effect with their current treatments.

“The lack of effective and safe drugs, combined with the fact that upwards of 8% of the adult population suffers from neuropathic pain, makes clear the great medical need and the enormous potential of our project. ACD440 can become a first-inclass drug and meet a very large patient need, which of cause is a value driver in connection with the outlicensing of the project”, said Martin Jönsson, CEO of AlzeCure Pharma.

KENNY FAMILY PRESENTS

CHEQUE FOR ¤40,500 TO UNIVERSITY HOSPITAL GALWAY

A very generous donation of ¤40,500 was recently presented to the Intensive Care Unit and the Patient Comfort Fund at University Hospital Galway (UHG) in memory of the late Mary Kenny from Loughrea, Co Galway. In addition, ¤5,000 was donated to Strange Boat Donor Foundation – The National Organ Donor Commemorative Garden (Circle of Life) located in Galway, and ¤2,000 to Quest Brain Injury Services, Galway.

The cheque was presented to the Intensive Care Unit and the Patient Comfort Fund, by John and Isabelle Kenny (husband and daughter of the late Mary

Kenny). The funds were raised through activities which included a GoFundMe page and a coffee morning bonanza at the Willow Café in conjunction with The Woodford Garden Centre. An evening of music was held in Carton House, as well as a raffle and spot prizes sponsored by local businesses. Finally, 20 brave individuals ‘Jumped for Mary’ by participating in a sky dive. John and Isabelle Kenny expressed their gratitude and said, “We would like to thank the doctors and nurses who cared for Mary in her final days. The medical and nursing team supported us to make the final decision to entrust Mary to the angels and to donate Mary’s organs, saving three people’s lives. To this dedicated, professional, supportive and compassionate team – from our family to yours we say a heartfelt thank you.”

Gillian Shanahan, Organ Donation Nurse Manager said, “We are forever humbled by organ donors and their families who find the strength in their depths of grief, to give the gift of life. On behalf of

Pictured at the cheque presentation to the Intensive Care Unit and Patient Comfort Fund at University Hospital Galway, from left front row: Bernie Moran; Edel Kelly, Assistant Directive of Nursing; John Kenny; Isabelle Kenny; Gillian Shanahan, Organ Donation Nurse Manager; Emma Gunning; Yvonne Shaw, Clinical Nurse Manager 2, ICU; Angela Burke O’Brien, Clinical Nurse Manager 2, ICU

From left back row: Pauline May, Assistant Director of Nursing /Former Organ Donation Nurse Manager; Pat Kenny; Dr John Bates, Consultant Intensivist; Ann Sheehan, Clinical Facilitator; myself and the team at University Hospital Galway we would like to express our sincere gratitude to all those involved for their time and efforts in raising this substantial amount. The money will be used to improve the comfort and experience of patients and their families during their stay in the Intensive Care Unit.”

New Data Which May Show Indicator Of Osteoporosis

Findings from a recent survey found that one in five (22%) adults have broken or fractured a bone since they turned 40 years of age. Over a third (35%) of these patients reported to have had a fragility fracture.1 Osteoporosis is a condition that causes bones to become weakened which can lead to fragility fractures. A fragility fracture is a broken bone that occurs due to minimal trauma, such as from a fall from standing height or less. Surprisingly, the rate of fragility fractures was high amongst 40-54 year olds with almost one in five (18%) surveyed having sustained a fragility fracture. This level of fractures would generally be expected amongst older age groups.

The research commissioned by Athena Pharmaceuticals surveyed 600 Irish men and women aged 40-90 to understand the occurrence of fragility fractures and awareness of appropriate nutritional supplementation for optimal bone health as people advance in age. The findings revealed a significant lack of awareness and confusion regarding the recommended daily allowances (RDA) of both Calcium and Vitamin D. 85% of adults are unaware of the correct amount of Calcium they require daily and 90% are unclear on the correct amount of Vitamin D required for optimal bone health.1

Diet is a major contributor to optimal bone health. The recommended daily allowance of calcium and Vitamin D as defined by the Institute of Medicine and Food Safety Authority of Ireland4 is outlined in table 1. Calcium intake may be achieved by consuming three portions of any of the following: 1 glass (200ml) of milk, 1 carton (125g) yoghurt, 1 bottle (200ml) yoghurt drink, 2 thumbs (25g) of hard or semi hard cheese such as cheddar or edam or 2 thumbs (25g) soft cheese such as brie or camembert. Of those surveyed, over three-quarters (76%) of men and women above 40 years old are not getting the appropriate amounts of calcium in their diet, only consuming <50% of the RDA. Worryingly, 80% of adults who have a history of a fragility fracture are not consuming adequate calcium and alarmingly, 7% report they are consuming none. Vitamin D5 is available from two sources, sunlight exposure during the summer months and diet. Sources include natural foods such as egg yolks and oily fish, and fortified foods such as cheese and milk drinks. Supplements are usually necessary to get the recommended amount. But this survey found that 90% of people are unsure of the daily vitamin D requirements.

Dr Miriam Delaney, Specialist in Osteoporosis, Metabolic Bone Disorders and Calcium Metabolism at the Galway Clinic and Athena Pharmaceuticals Spokesperson, said: “It is important that people build and maintain their ‘bone bank’ throughout their lives. Anyone who has had a fragility fracture over the age of 40, is considered at high risk of osteoporosis and should discuss evaluation and treatment with their doctor. Achieving bone health may include behavioural changes, such as improving diet, engaging in weight-bearing exercise and taking oral supplements of calcium and vitamin D, if required.

“Eating behaviours have changed drastically over the past three decades with our families and children eating very differently to how we, or our parents, would have eaten in the past. We develop our bone bank during our early decades of life and after achieving peak bone mass, we naturally lose bone mass with ageing. Hence it is essential that our diet provides us with sufficient calcium and vitamin D, to minimise bone loss as we age. People with little or no calcium in their diet are at elevated risk of osteoporosis and fractures in later years. Falling and fracturing the hip or spine, is a major cause of longterm pain, decreased mobility, loss of independence, hospitalisation and death in the elderly.

Individuals at a higher risk of Osteoporosis include those with many underlying illnesses, or taking certain medications such as oral steroids (for asthma or COPD), patients being treated for cancer, those with limited mobility, those in care homes or hospitals, etc and should be recognised as being at risk of weakened bones as a result of their underlying illness and treatment.6

When supplementation is deemed necessary, it is important that people get expert advice from their pharmacist or healthcare provider.”

For more information about the risk factors, assessment and treatment of osteoporosis visit https://www.osteoporosis. foundation/educational-hub/ material/patient-resources

2023 TRANSPLANT GAMES

Fourteen Irish transplant recipients will travel to Perth, Australia this month to represent Ireland at the World Transplant Games (15-21 April). This follows a four-year hiatus for the biennial World Transplant Games, as the previous event planned for 2021 had to be cancelled due to the global COVID-19 pandemic. The Irish squad gathered at the ALSAA Sports Complex, Dublin airport on Sunday, 12th March and were joined by family, friends and other members of the Transplant Team

Ireland programme, to receive their official team kit. The guest speaker at the event organised by the Irish Kidney Association was former Olympian triathlete Gavin Noble, the Olympic Federation of Ireland’s Chef de Mission for the Paris 2024 Olympic Games and 2023 European Games.

Ranging in age from 36 right up to 75, the current Transplant Team Ireland panel of 10 inspirational men and 4 women travelling to Perth have all received organ transplants including 2 liver, 2 bone marrow, and 10 kidney. They will be among over 1,200 participants from over 50 countries, all embracing their gift of life and honoring their donors in this celebration of life through sport.

In his talk to Transplant Team Ireland, Gavin Noble shared some of the wisdom he gained from the lead up to, and participation in, the 2012 Olympic Games in London and how he is now invested into helping other athletes be the best that they can be. He said, “Each and every one of you on the Transplant Team are an inspiration as you are living your best life, honouring your donors and representing your country in sport. Sport brings people together as does organ donation”.

The Irish Kidney Association is responsible for managing and supporting Transplant Team Ireland’s involvement at the Games and its National Advocacy and Projects Manager Colin White is the Team Manager.

To find out more about the World Transplant Games visit website www.worldtransplantgames.org and to find out more about members of Transplant Team Ireland and to follow their progress at the Games, you can follow the team blog; www.transplantteamireland.ie

SANOFI TO ACQUIRE PROVENTION BIO, ADDING TO PORTFOLIO TZIELD, THE FIRST DISEASE-MODIFYING TREATMENT FOR THE DELAY OF STAGE 3 TYPE 1 DIABETES (T1D) Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered into an agreement under which Sanofi has agreed to acquire Provention Bio, Inc., for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.

Transplant Team Ireland members pictured at a team gathering in preparation for The World Transplant Games held in Perth, Australia next month. Transplant Team Ireland's participation at the Games is managed by the Irish Kidney Association. Fourteen inspirational Irish men and women who have received liver, kidney and bone marrow transplants will travel to Perth, Australia next month to represent Ireland at the World Transplant Games (15-21 April). Picture Conor McCabe Photography